Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Clinical trial enrollment has long been a bottleneck in drug development
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
The inspection concluded with one minor observation in Form 483
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Subscribe To Our Newsletter & Stay Updated